BioAlliance Pharma and Topotarget's new merged company Onxeo makes 1st-half 2014 operating loss
Orphan oncology drug specialist Onxeo (Euronext Paris: ONXEO), created by a merger between French company BioAlliance Pharma, and Danish biopharmaceutical company Topotarget, has made an operating loss in the first half of 2014, but are laying the foundations for the new company.
It reported revenues of 6.5 million euros ($8.8 million), a loss of 23% on BioAlliance’s figures for the same half in 2013, although the figures it has reported do not include the strengthening of its cash level brought about by the 14.2 million euro contribution from the merger with Topotarget, which only took place on June 30. This amount includes milestones received from Spectrum Pharmaceuticals earlier this year upon the acceptance of Belodaq’s New Drug Application from the US Food and Drug Administration.
Gained FDA 'fast track' designation for Livatag
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze